Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc News
Centessa Pharmaceuticals plc Quantitative Score
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Centessa Pharmaceuticals plc Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Centessa Pharmaceuticals plc Financials
Table Compare
Compare CNTA metrics with: | |||
|---|---|---|---|
Earnings & Growth | CNTA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CNTA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CNTA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CNTA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Centessa Pharmaceuticals plc Income
Centessa Pharmaceuticals plc Balance Sheet
Centessa Pharmaceuticals plc Cash Flow
Centessa Pharmaceuticals plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Centessa Pharmaceuticals plc Executives
| Name | Role |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer & Director |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Mr. John J. Crowley CPA | Chief Financial Officer & Principal Financial Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Mr. Raphael Deferiere CPA | Chief Accounting Officer & Principal Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer & Director | 1976 | 1.23M | |
| Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary | Male | 1981 | 768.58K |
| Mr. John J. Crowley CPA | Chief Financial Officer & Principal Financial Officer | Male | 1974 | 682.03K |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer | 1971 | 655K | |
| Mr. Raphael Deferiere CPA | Chief Accounting Officer & Principal Accounting Officer | Male | 1979 | -- |
Centessa Pharmaceuticals plc Insider Trades
| Date | 17 Nov |
| Name | HUSSAIN IQBAL J |
| Role | General Counsel |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 6000 |
| Date | 17 Nov |
| Name | HUSSAIN IQBAL J |
| Role | General Counsel |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 6000 |
| Date | 17 Nov |
| Name | HUSSAIN IQBAL J |
| Role | General Counsel |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 6000 |
| Date | 17 Nov |
| Name | Bush Tia L |
| Role | Chief Technology & Quality Ofc |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 40000 |
| Date | 17 Nov |
| Name | Bush Tia L |
| Role | Chief Technology & Quality Ofc |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 40000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 17 Nov | HUSSAIN IQBAL J | General Counsel | Acquired | M-Exempt | 6000 |
| 17 Nov | HUSSAIN IQBAL J | General Counsel | Disposed | S-Sale | 6000 |
| 17 Nov | HUSSAIN IQBAL J | General Counsel | Disposed | M-Exempt | 6000 |
| 17 Nov | Bush Tia L | Chief Technology & Quality Ofc | Acquired | M-Exempt | 40000 |
| 17 Nov | Bush Tia L | Chief Technology & Quality Ofc | Disposed | S-Sale | 40000 |